Indivior Pharmaceuticals Inc. (INDV)
NASDAQ: INDVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
INDV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.26B
- P/E (TTM)
- 12.95
- Forward P/E
- 7.40
- EPS (TTM)
- $2.79
- Dividend yield
- None
- 52-week range
- 22.95 – 42.81
- Day range
- 35.58 – 36.30
- Volume / Avg
- 1.59M / 2.07M
- Beta
- —
- Shares outstanding
- 118.03M
- Next earnings
- Oct 29, 2026
52-week range
INDV stock today
Shares of Indivior Pharmaceuticals (INDV) finished higher on Oct 7 at $36.13, a gain of 0.64% or $0.23 per share, versus the S&P 500's 0.22% decline. Shares are 15.6% below their 52-week high of $42.81, set on Jun 26, 2026 and 57.4% above the 52-week low of $22.95, in the middle of the past year's range. INDV is up 0.7% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 52.3%.
Indivior Pharmaceuticals trades at 12.9x its trailing twelve-month earnings per share of $2.79. Its forward P/E of 7.4x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. Indivior Pharmaceuticals's next earnings report is expected on Oct 29, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Indivior Pharmaceuticals
Company profileIndivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Joseph J. Ciaffoni
- Headquarters
- North Chesterfield, VA
- Employees
- 827
- Website
- indivior.com
Financial highlights
Full financialsIn fiscal 2025, Indivior Pharmaceuticals generated $1.24 billion in revenue, up 4.3% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $210.0 million (+2900.0% year over year), for a net margin of 16.9% versus a median of -2.0% in the prior 4 years. Gross margin was 80.2% (down from 80.6%) and operating margin 21.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.24B | $1.19B | $1.09B | $901.00M | $791.00M |
| Growth | +4.29% | +8.69% | +21.31% | +13.91% | — |
| Net income | $210.00M | $7.00M | $-126.00M | $-42.00M | $205.00M |
| EPS (diluted) | $1.64 | $0.05 | $-0.92 | $-0.30 | — |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$49.00+35.62%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 29, 2026
- EPS estimate
- $0.93
- Last reported (Q2 2026)
- Aug 3, 2026
- EPS actual vs est.
- $0.98 vs —
Indivior Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EWTXEdgewise Therapeutics Inc. | 39.57 | -1.12% | $4.30B | vs INDV |
| ABCLAbCellera Biologics Inc. | 12.83 | -2.43% | $4.16B | vs INDV |
| MANEVeradermics Incorporated | 110.95 | +1.83% | $4.64B | vs INDV |
| TLXTelix Pharmaceuticals Limited ADR | 11.12 | +3.15% | $3.78B | vs INDV |
| LEGNLegend Biotech Corporation ADR | 19.12 | +2.14% | $3.72B | vs INDV |
| VKTXViking Therapeutics Inc. | 28.54 | +0.56% | $3.63B | vs INDV |
| PBLSParabilis Medicines Inc. | 28.82 | -0.14% | $3.56B | vs INDV |
| ERASErasca Inc. | 14.12 | -1.26% | $4.94B | vs INDV |
Indexes, lists and sector
Indivior Pharmaceuticals stock FAQ
What is Indivior Pharmaceuticals's stock price today?
INDV last traded at $36.13 as of Oct 7, 4:00 PM EDT, up 0.64% on the day. Prices are delayed at least 15 minutes.
When is Indivior Pharmaceuticals's next earnings date?
Indivior Pharmaceuticals is expected to report earnings on Thursday, October 29, 2026. Analysts expect EPS of $0.93.
What is INDV's P/E ratio?
INDV trades at a trailing P/E ratio of 12.95 and a forward P/E of 7.40.
Who is Indivior Pharmaceuticals's CEO?
Mr. Joseph J. Ciaffoni is the chief executive officer of Indivior Pharmaceuticals Inc., which has about 827 employees.
What is the INDV 52-week high?
The 52-week high for INDV is $42.81 and the 52-week low is $22.95. The stock is currently 15.6% below its high.